ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,525Medicare Part D Prescriptions Filled, Including Refills

Rank: 142 out of 1278

$529K Total Retail Price of All Prescriptions

Rank: 108 out of 1278

448 Patients Receiving at Least One Drug in Part D
77%Patients 65 Years and Older
47% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arizona
Lower avg

Schedule Two
Controlled Substances

14% of this provider’s 448 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

17% of this provider’s 448 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

3% of this provider’s 5,724 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$62 was the average price of a prescription from this provider, compared to $57 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 14.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arizona
LEVOTHYROXINE SODIUM 489 393 1 2
HYDROCODONE-ACETAMINOPHEN 358 205 S3 2 7
LISINOPRIL 351 260 3 1
AMLODIPINE BESYLATE 218 195 4 5
HYDROCHLOROTHIAZIDE 182 151 5 8
SIMVASTATIN 169 143 6 3
LOVASTATIN 162 125 7 13
ZOLPIDEM TARTRATE 162 89 7 16
OMEPRAZOLE 149 122 9 6
METFORMIN HCL 133 113 10 4
WARFARIN SODIUM 122 107 11 17
METOPROLOL TARTRATE 119 93 12 9
FUROSEMIDE 111 96 13 10
CITALOPRAM HBR 108 80 14 22
RANITIDINE HCL 98 53 15 20
CARISOPRODOL 95 25 R 16 51
TRAMADOL HCL 94 44 17 25
PROAIR HFA 92 38 18 26
PRAVASTATIN SODIUM 90 90 19 14
OXYCODONE HCL-ACETAMINOPHEN 84 14 S2 20 76
POTASSIUM CHLORIDE 83 67 21 21
FLUTICASONE PROPIONATE 83 45 21 24
SERTRALINE HCL 81 58 23 28
ATENOLOL 81 64 23 11
VENLAFAXINE HCL ER 77 29 25 121
TRAZODONE HCL 77 48 25 38
OXYCODONE HCL 76 24 S2 27 27
ALENDRONATE SODIUM 75 64 28 18
PANTOPRAZOLE SODIUM 75 41 28 34
AMITRIPTYLINE HCL 71 53 R 30 55
ADVAIR DISKUS 71 45 30 49
ATORVASTATIN CALCIUM 71 69 30 15
LOSARTAN POTASSIUM 70 67 33 19
CLOPIDOGREL 68 59 34 45
ESTRADIOL 68 38 R 34 71
METOPROLOL SUCCINATE 68 29 34 23
CRESTOR 67 48 37 31
GABAPENTIN 66 43 38 12
CARVEDILOL 60 55 39 39
CYMBALTA 58 23 40 67
NEXIUM 57 35 41 106
LEVOXYL 56 35 42 94
MORPHINE SULFATE ER 52 25 S2 43 42
ALLOPURINOL 51 20 44 36
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 16, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.